Details for Patent: 6,956,060
✉ Email this page to a colleague
Title: | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
Abstract: | The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an effective illness, a neurodegenerative disease, a neurotoxic injury, stroke, brain ischemia, a head trauma injury, a spinal trauma injury, neurotrauma, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject. Finally, the subject invention provides methods of preparing R(+)-N-propargyl-1-aminoindan, a salt thereof, and racemic N-propargyl-1-aminoindan. |
Inventor(s): | Youdim; Moussa B. H. (Tivon, IL), Finberg; John P. M. (Tivon, IL), Levy; Ruth (Tel-Aviv, IL), Sterling; Jeffrey (Jerusalem, IL), Lerner; David (Jerusalem, IL), Yellin; Haim (Ramat-Gan, IL), Veinberg; Alex (Rehovot, IL) |
Assignee: | Teva Pharmaceutical Industries, Ltd. (Petach-Tikva, IL) Technion Research and Development Foundation Ltd. (Haifa, IL) |
Filing Date: | Nov 27, 2002 |
Application Number: | 10/305,478 |
Claims: | 1. A pharmaceutically acceptable salt of R(+)-N-propargyl-1-aminoindan, wherein the salt is the tartrate salt. 2. A pharmaceutical composition consisting essentially of the pharmaceutically acceptable salt of claim 1 and a pharmaceutically acceptable carrier. 3. A pharmaceutical composition comprising the pharmaceutically acceptable salt of claim 1 and a pharmaceutically acceptable carrier. 4. A pharmaceutical composition consisting of the pharmaceutically acceptable salt of claim 1 and a pharmaceutically acceptable carrier. 5. A pharmaceutical composition consisting of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt and a carrier. |